60,189 Shares in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Purchased by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company purchased a new stake in shares of Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) in the second quarter, Holdings Channel.com reports. The firm purchased 60,189 shares of the company’s stock, valued at approximately $280,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Affinity Asset Advisors LLC bought a new stake in shares of Black Diamond Therapeutics in the 2nd quarter worth $3,029,000. Marshall Wace LLP bought a new position in shares of Black Diamond Therapeutics during the second quarter valued at about $441,000. Ally Bridge Group NY LLC purchased a new position in Black Diamond Therapeutics during the second quarter worth about $3,891,000. Renaissance Technologies LLC grew its position in Black Diamond Therapeutics by 24.1% in the 2nd quarter. Renaissance Technologies LLC now owns 263,900 shares of the company’s stock worth $1,230,000 after purchasing an additional 51,300 shares in the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Black Diamond Therapeutics by 79.1% in the 2nd quarter. Dimensional Fund Advisors LP now owns 200,044 shares of the company’s stock valued at $932,000 after buying an additional 88,378 shares during the last quarter. 95.47% of the stock is owned by institutional investors.

Analyst Ratings Changes

BDTX has been the topic of a number of research analyst reports. Wedbush restated an “outperform” rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. Piper Sandler boosted their price objective on Black Diamond Therapeutics from $12.00 to $15.00 and gave the stock an “overweight” rating in a research report on Monday, September 23rd. HC Wainwright restated a “buy” rating and issued a $11.00 price objective on shares of Black Diamond Therapeutics in a research note on Wednesday, October 9th. Finally, Raymond James initiated coverage on Black Diamond Therapeutics in a research note on Wednesday, July 31st. They set an “outperform” rating and a $20.00 target price on the stock.

Black Diamond Therapeutics Trading Down 5.3 %

NASDAQ:BDTX opened at $3.22 on Friday. Black Diamond Therapeutics, Inc. has a 12 month low of $1.62 and a 12 month high of $7.66. The firm’s 50 day moving average is $4.95 and its 200 day moving average is $5.23. The stock has a market capitalization of $181.13 million, a PE ratio of -1.94 and a beta of 2.47.

Black Diamond Therapeutics (NASDAQ:BDTX) last issued its earnings results on Tuesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.03. Research analysts predict that Black Diamond Therapeutics, Inc. will post -1.44 earnings per share for the current year.

Black Diamond Therapeutics Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.